AURIGENE ONCOLOGY LIMITED

Nature of Business: Manufacturer / Research & Development Company

Company Introduction:

Aurigene Oncology Limited is an India-based biopharmaceutical company primarily dedicated to the discovery and development of novel small molecule and peptide drugs. Its core focus lies in oncology (cancer) and inflammatory diseases. As a key entity, often associated with Aurigene Discovery Technologies Limited, the company engages in comprehensive drug discovery programs, from initial target identification and validation through lead optimization and preclinical development.

Aurigene leverages its deep scientific expertise in medicinal chemistry, biology, and pharmacology to innovate and advance drug candidates. Their business model includes developing proprietary drug candidates internally and forging strategic collaborations and licensing partnerships with global pharmaceutical companies to bring these innovative therapies to clinical trials and ultimately to market. They are committed to addressing unmet medical needs by translating cutting-edge scientific research into potential therapeutic solutions.

Aurigene Oncology Limited is not a trading company; instead, it is actively involved in the fundamental research, development, and creation of new therapeutic molecules, positioning it as a manufacturer and innovator in the biopharmaceutical industry.

AURIGENE ONCOLOGY LIMITED, an Indian company, provides comprehensive oncology solutions, including:

* **Drug Discovery Services:** Target identification and validation, assay development, high-throughput screening, lead optimization, and preclinical development.

* **Preclinical Research Services:** In vitro and in vivo pharmacology, toxicology, and pharmacokinetic/pharmacodynamic (PK/PD) studies.

* **Clinical Research Services:** Bioanalytical services, clinical trial management, and data management.

* **Genomics Services:** Gene expression profiling, next-generation sequencing, and bioinformatics.

* **Contract Manufacturing:** Manufacturing of drug substances and drug products for clinical trials and commercial supply.

* **Specialized Oncology Models:** A wide range of patient-derived xenograft (PDX) models and cell line-derived xenograft (CDX) models for preclinical oncology research.